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Abstract
Objectives. Adoptive transfer of chimeric antigen receptor (CAR)-
modified T cells is a form of cancer immunotherapy that has
achieved remarkable efficacy in patients with some
haematological cancers. However, challenges remain in CAR T-cell
treatment of solid tumours because of tumour-mediated
immunosuppression. Methods. We have demonstrated that CAR T-
cell stimulation through T-cell receptors (TCRs) in vivo can
generate durable responses against solid tumours in a variety of
murine models. Since Clec9A-targeting tailored nanoemulsion
(Clec9A-TNE) vaccine enhances antitumour immune responses
through selective activation of Clec9A+ cross-presenting dendritic
cells (DCs), we hypothesised that Clec9A-TNE could prime DCs for
antigen presentation to CAR T cells through TCRs and thus
improve CAR T-cell responses against solid tumours. To test this
hypothesis, we used CAR T cells expressing transgenic TCRs specific
for ovalbumin (OVA) peptides SIINFEKL (CAROTI) or OVA323-339
(CAROTII). Results. We demonstrated that the Clec9A-TNEs
encapsulating full-length recombinant OVA protein (OVA-Clec9A-
TNE) improved CAROT T-cell proliferation and inflammatory
cytokine secretion in vitro. Combined treatment using the OVA-
Clec9A-TNE and CAROT cells resulted in durable responses and
some rejections of tumours in immunocompetent mice. Tumour
regression was accompanied by enhanced CAROT cell proliferation
and infiltration into the tumours. Conclusion. Our study presents
Clec9A-TNE as a prospective avenue to enhance CAR T-cell efficacy
for solid cancers.
Keywords: CAR T cells, Clec9A, cross-presentation, dendritic cells,
nanoemulsion, vaccine
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INTRODUCTION
Chimeric antigen receptor (CAR) T-cell treatment
against blood cancers has been promising,
demonstrating significant responses in patients
with certain B-cell malignancies.1–3 The success of
CAR T-cell treatment has resulted in FDA
approvals for two CAR T-cell therapies, including
CD19 CAR T-cell therapies for the treatment of
children and adolescents with acute lymphoblastic
leukaemia (ALL) and adults with relapsed-
refractory large B-cell lymphoma in 2017. Despite
the successes in treating these haematological
cancers, clinical trials targeting solid tumours have
demonstrated a mostly inadequate efficacy. This is
largely attributed to the immunosuppressive
tumour microenvironment (TME) that inhibits T-
cell function, and to the poor trafficking of CAR T
cells to the tumour sites.4,5
In a previous study, we utilised ‘CARaMEL’ dual-
specific T cells, expressing a CAR specific for Her2
tumour antigen, and a T-cell receptor (TCR)
specific for a strong, tumour-unrelated
immunogen, the melanocyte protein gp100 (also
known as pMEL). When the CARaMEL T cells were
used in combination with a live vaccinia viral
vaccine encoding gp100 (VV-gp100), the
treatment induced dramatic CAR T-cell expansion
in vivo through the stimulation of gp100 TCR and
resulted in the eradication of large tumours and
metastases in a number of murine Her2 tumour
models.6 Despite the successes of this dual-specific
CAR T-cell approach, it would be ideal to develop
a more convenient and readily approvable vaccine
that does not involve a live virus.
Recently, we used a tailored nanoemulsion (TNE)
to encapsulate tumour antigens for the
presentation to the cross-presenting dendritic cells
(DC) through the specific receptor Clec9A (Clec9A-
TNE).7 Clec9A recognises the necrotic cell ligand F-
actin for the uptake of cell-derived antigens, which
are processed for MHC class I and class II
presentation.8 When OVA protein was encapsulated
into Clec9A-TNE (OVA-Clec9A-TNE), it demonstrated
effective targeting and activation of cross-
presenting DCs, even in the absence of additional
adjuvant, and generated greater OVA-specific T-cell
expansion than antibody-based targeting of OVA to
Clec9A+ DCs in mice. Effective priming of OVA-
specific T cells significantly delayed tumour growth
and improved survival in mice bearing orthotopic
OVA-expressing tumours. This effect also
extended to Clec9A-TNEs carrying B16F10 tumour
neo-epitopes. These TNEs elicited epitope-specific
T-cell responses that significantly delayed tumour
growth and enhanced the survival of tumour-
bearing mice in an epitope-specific manner.7
In the current study, we hypothesised that
Clec9A-TNE could prime DCs for antigen
presentation to CAR T cells through TCRs and thus
improve CAR T-cell responses against solid
tumours. We used the dual-specific CAR T cells
expressing a second-generation anti-Her2 CAR
(CD3-f/CD28), and OTI or OTII TCRs (CAROTI TCR
specific to the OVA peptide SIINFEKL or CAROTII
TCR specific to OVA323-339).
9,10 Thus, the CAROT
cells have dual specificity for Her2 and OVA
peptide antigens through their CARs and TCRs,
respectively. We aimed to investigate whether the
OVA-Clec9A-TNE could facilitate antigen
presentation to the TCRs of CAROT cells, thereby
enhancing CAROT cell activation in vitro and
antitumour responses in vivo.
RESULTS
Dual-specific CAROTI and CAROTII cells
express CAR and OVA-specific TCRs
In this study, we crossed C57BL/6 Her2-CAR
transgenic mice to the OTI or OTII mice.9,10 The
cells from the Her2-CAR mice express a second-
generation CAR (anti-Her2-CD28-CD3f) driven by a
vav promoter.11 Thus, all of the T cells from the
resulting CAROT mice express both a CAR specific
for Her2 and a TCR specific for OVA, derived
either from OTI for CD8 T cells or OTII for CD4 T
cells. We refer to these mice and T cells as
CAROTI12 and CAROTII. To confirm co-expression
of the CAR and TCR, splenocytes were harvested
from CAROTI and CAROTII mice and stained with
fluorochrome-conjugated antibodies specific for a
c-Myc tag included in the CAR construct, and the
TCR Va2 chain that comprises OTI and OTII TCRs
(Figure 1a). By using the gating strategy detailed
in Figure 1a, we found simultaneous, high-level
CAR and TCR Va2 expression on CAROTI and
CAROTII T cells (Figure 1b). The dual-specific
CAROTI cells were mostly CD8+, while dual-specific
CAROTII cells were mostly CD4+ (Figure 1c).
CAROT T cells respond through their TCR
and CAR
We next investigated whether TCRs and CAR on the
CAROT T cells could respond to cognate peptide
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Figure 1. CAROTI and CAROTII expressing anti-Her2 CAR and TCR Va2. Splenocytes isolated from CAROTI, CAROTII and WT mice were stained
with a viability marker (fluorogold) and antibodies against CD4, CD8, TCR Va2 and c-Myc tag (CAR). Cells were phenotypically analysed by flow
cytometry for CD4, CD8, anti-Her2 CAR and TCR Va2 expression on viable cells. (a) Gating strategy and representative plots of CAROTI and
CAROTII cells co-expressing the anti-Her2 CAR and TCR Va2 of two independent experiments. (b) Anti-Her2 CAR and TCR Va2 co-expression as
a percentage of total lymphocytes. (c) CAROTI and CAROTII CD4 and CD8 percentages of dual-specific CAROT cells. (b, c) Data are represented
as the mean  the standard error of the mean (SEM) and are pooled from two independent experiments in triplicates. Statistical significance was
determined by one-way ANOVA. *P < 0.05, **P < 0.01, ****P < 0.0001.
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antigens. To test TCR function, CAROTI and
CAROTII splenocytes were incubated with peptides
cognate for their corresponding OTI and OTII TCRs
(SIINFEKL and OVA323-339, respectively). The CAROTI
and CAROTII splenocytes and culture supernatants
were then harvested for flow cytometric and
cytometric bead assay (CBA) analysis. Based on
expression levels of CD44 and CD62L, CAROT
cells were classified as CD44LowCD62LHigh,
CD44HighCD62LHigh, CD44HighCD62LLow and
CD44LowCD62LLow populations. In response to
cognate peptide antigens, both CAROTI and
CAROTII cells were predominantly
CD44HighCD62LHigh (Figure 2a–c).
When cultured with their respective cognate
peptides, CAROTI and CAROTII cells secreted IL-2,
IFN-c and TNF-a (Figure 2d–f), confirming that
CAROT cells express functional OTI/OTII TCRs and
that stimulation through the TCRs could activate
CAROT cells.
To confirm the functional capacity of the anti-
Her2 CAR, we determined whether CAROT cells
could kill Her2+ tumour cells in an antigen-
dependent manner. Uniformly high Her2
expression was confirmed on E0771-Her2 tumour
cells, using flow cytometry (Supplementary figure
1). After activation with their respective cognate
peptide antigens for 7 days, CAROTI and CAROTII
cells mediated strong Her2-specific cytolysis of
tumour cells (Figure 2g and h).
In summary, CAROTI and CAROTII cells have a
functional anti-Her2 CAR that can mediate Her2-
specific killing and OVA-specific TCRs that can
activate the CAROT T cells.
OVA-Clec9A-TNE drives CAROTI and CAROTII
cell activation
To evaluate whether OVA-Clec9A-TNE can activate
CAROT cells, we stimulated the cells with 50 nM
full-length OVA protein or the OVA-Clec9A-TNE
in vitro. An empty-vehicle Clec9A-TNE was used to
assess any non-specific effects that the
nanoemulsion may produce. OVA-Clec9A-TNE
stimulated CAROTI and CAROTII cell proliferation
comparably to OVA protein, as was reflected both
by cell counts (Figure 3a and b) and CFSE dilution
(Figure 3c). The empty-vehicle Clec9A-TNE caused
no proliferation above the medium only control.
After incubation with the OVA-Clec9A-TNE, a
significant proportion of CAROTI and CAROTII
cells were phenotypically CD44HighCD62LHigh
(Figure 3d), as occurred when the cells were
stimulated with their cognate peptides (Figure 2c).
Interestingly, CAROTI cells included a significant
proportion of CD44LowCD62LHigh cells signifying
na€ıve or stem cell memory-like phenotype,
whereas CAROTII cells had a greater percentage of
CD62LLowCD44High cells, characteristic of an
effector phenotype. We further analysed the CFSE
labelled CAROTI cells presented in Figure 3c and
found that the majority of the CD44LowCD62LHigh
cells were CFSEHigh (Supplementary figure 2),
indicating that these cells were na€ıve and had not
been stimulated. CAROTI, but not CAROTII cells,
secreted significantly higher levels of IFN-c when
cultured with OVA-Clec9A-TNE than when cultured
with TNE vehicle control (Figure 3e and f).
OVA-Clec9A-TNE augments CAROT cell
antitumour function in vivo
We have demonstrated that TCR stimulation of
dual-specific T cells with a live virus vaccine can
drive durable, complete remission of a variety of
Her2 expressing tumours in vivo.6,13 To maximise
the opportunity for clinical translation, we now
aim to achieve similar outcomes using a more
generic and clinically tractable approach that does
not require administering a live virus. To this end,
we used immunocompetent, transgenic C57BL/6-
Her2 mice that are fully tolerant of, and
constitutively express human Her2 in breast
epithelium and cerebellar cortex, and are also
permissive for the growth of Her2 expressing
tumours of C57BL/6 origin.14,15
In the Her2 transgenic mice bearing E0771-Her2
breast cancers, we observed significant tumour
growth inhibition in mice receiving both
adoptively transferred CAROT cells
(CAROTI+CAROTII) and injections of OVA-Clec9A-
TNE (the treatment scheme is described in
Figure 4a). In contrast, CAROT cell- or OVA-
Clec9A-TNE treatment alone had a lesser
antitumour effect (Figure 4b). In fact, tumours in
some mice that received the combination therapy
regressed completely, leading to long-term
survival (Figure 4c). In contrast, none of the mice
in the no treatment group or the OVA-Clec9A-
TNE-treated group survived beyond day 14.
Similar results were obtained in Her2-transgenic
C57BL/6 mice bearing MC38-Her2 tumours.
Significant tumour growth inhibition (Figure 4d)
and prolonged survival (Figure 4e) were observed
in mice receiving CAROT cells and OVA-Clec9A-
TNE in combination.
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Figure 2. CAROTI and CAROTII cells express functional transgenic TCRs and CARs. CAROTI or II splenocytes were stimulated with 5 lM SIINFEKL
or OVA323-339, respectively, over 48 h. WT splenocytes were used as the experimental control. Splenocytes cultured in medium (no stimulation) or
aCD3 (0.5 lg mL1) and aCD28 (0.5 lg mL1) were used as negative and positive controls, respectively. Cells were analysed via flow cytometry
and cultured with 51Cr labelled E0771-Her2 or E0771-LMC tumour cells to test CAROT cell cytotoxicity. Supernatants were harvested and
analysed for cytokine secretion. (a, b) Representative CD44 and CD62L expression of CAROT cells. (c) Percentages of CAROTI and CAROTII cells
expressing CD44 and CD62L after stimulated with 5 lM SIINFEKL or OVA323-339, respectively, over 48 h. (d) IL-2, (e) IFN-c and (f) TNF-a levels in
the cell culture supernatant. (g, h) Chromium release assay of CAROT cells against Her2+ (E0771-Her2) and Her2 (E0771-LMC) cancer targets.
Data are presented as mean  SEM from three independent experiments in triplicates. Significance was calculated using one-way ANOVA.
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns = not significant.
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We did not observe overt signs of toxicity such
as breast or cerebellar inflammation in the
treated mice. In addition, to assess potential
cytokine hypersecretion associated with the
treatment, serum cytokine levels were measured.
The pro-inflammatory cytokines IL-12, IFN-c and
TNF-a, the pleiotropic cytokine IL-6 and the
immunosuppressive cytokine IL-10 were not
significantly elevated in any treatment group
(Figure 4f–j).
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Figure 3. OVA-Clec9A-TNE drives CAROT cell proliferation and IFN-c secretion. 1 9 106 CAROTI and CAROTII splenocytes labelled with 0.1 lM
CFSE (b) or without CFSE (a, c–f) were cultured over 72 and 96 h, respectively, with full-length OVA protein or OVA-Clec9A-TNE at an OVA
concentration of 50 nM. Splenocytes were cultured with an empty-vehicle TNE at dilutions corresponding to the amount of TNE added in OVA-
Clec9A-TNE cultures. Splenocytes cultured with media (no stimulation, represented with a horizontal bar where appropriate) or with soluble
aCD3 (0.5 lg mL1) and aCD28 (0.5 lg mL1) were used as negative and positive controls, respectively. Following culture, CAROT cells were
quantified via flow cytometric analysis and the amount of IFN-c secreted into supernatants was measured. (a) CAROTI and (b) CAROTII cell
counts in the splenocyte culture. (c) Representative histograms of CAROTI and CAROTII cell proliferation in CFSE dilution. (d) Percentages of
CAROTI and CAROTII cells showing high or low CD44 and CD62L expression following culture with OVA-Clec9A-TNE at a 50 nM OVA
concentration. (e) CAROTI and (f) CAROTII splenocyte culture IFN-c secretion. (a, b, d, e, f) Data are presented as mean  SEM pooled from
three independent experiments in triplicates. Statistical significance was determined using one-way ANOVA (*P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0001, ns = not significant).
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ns = not significant). Data are shown as mean  SEM of 5 or 6 mice per group from one experiment per tumour model.
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Combined OVA-Clec9A-TNE and CAROT
treatment generates an antitumour
memory response in the long-term
surviving mice
An important aim of immunotherapy is to
generate immune memory to prevent tumour
relapse. Therefore, we investigated whether
combining OVA-Clec9A-TNE and CAROT cells
could produce long-term protection. Mice from
the OVA-Clec9A-TNE and CAROT treatment group
that had completely rejected their tumour were
rechallenged with a further subcutaneous
inoculation of E0771-Her2 tumour cells in the
opposite flank after remaining tumour-free for
60 days. We observed no tumour growth in
rechallenged mice, while tumours grew
progressively in na€ıve control mice (Figure 5a). All
rechallenged mice achieved prolonged survival,
while na€ıve control mice did not survive beyond
22 days after tumour cell challenge (Figure 5b),
confirming that the combined therapy induced an
antitumour memory response.
OVA-Clec9A-TNE drives CAROTI cell
expansion and infiltration into the tumours
Spleens and tumours from tumour-bearing mice
were analysed 5 days post-therapy. We observed
significantly higher CAROTI cell numbers in the
spleens and tumours of mice administered OVA-
Clec9A-TNE and CAROT cell adoptive transfer
(Figure 6a and b) compared to the other
treatment groups. Surprisingly, there was no
significant increase in CAROTII cells in the spleens
or tumours of mice that received combination
therapy compared to untreated mice or mice that
received monotherapies. IHC analysis
demonstrated a dense tumour infiltration of CD8+
T cells in combination-treated mice, and the CD8+
T cells were evenly distributed in the tumour
tissue (Figure 6c and d).
Analysis of DC markers revealed a higher
proportion of cross-presenting CD11c+CD8+MHCIILow
and CD11c+CD8+MHCIIHigh DCs in the spleens and
tumours of mice administered combination
therapy (Figure 6e and f) when compared to
mice in other groups. It is interesting that the
CD11c+CD8+MHCIILow DC numbers were higher in
mice treated with combination therapy than the
OVA-Clec9A-TNE treatment alone group.
MHCIIlow DCs are reported to be immature DCs
whose MHCII is kept low through high
endocytosis and degradation in lysosomes.16
Likely the activation of CAROT cells and the
killing of the tumour cells induced elevated
levels of DC growth factors that promote the
differentiation of DC precursors to immature
DCs. These immature DCs were likely recruited to
the inflamed tumour site and kept in an
immature status alongside other immature
myeloid cells within the TME.
Functional endogenous immunity is
required for combination treatment efficacy
We next tested the efficacy of combining OVA-
Clec9A-TNE and CAROT cells in immunodeficient
NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice that
lack functional lymphocytes and have defective
DCs.17,18 In untreated and all treatment groups,
tumours grew progressively with no significant
difference in tumour growth (Figure 7a). There
was no significant difference in mouse survival
across all the groups, and no mice survived
beyond 16 days after the treatment (Figure 7b).
The results indicate a requirement for functional
endogenous immunity, likely antigen-presenting
cells (APCs) including cross-presenting DCs, for the
combination treatment to be effective.
In summary, combining dual-specific CAROT
cells and OVA-Clec9A-TNE resulted in significant
tumour regression, led to long-term survival and
generated antitumour memory in
immunocompetent murine tumour models. The
shrinkage of tumours was accompanied by
significant CD8+ CAROTI cell expansion and
tumour infiltration. The endogenous immune
system, likely the functioning of cross-presenting
DCs, was necessary for the antitumour effect.
DISCUSSION
While remarkably efficacious in patients with acute
B-cell leukaemia and some B lymphomas, CAR T
cells have far more limited efficacy in solid tumours
because of the immunosuppressive TME.19 In this
study, we exploited a nanoparticulate vaccination
platform for cross-priming CAR T cells by cross-
presenting DCs, which are present in lymphoid
organs and tumours. Here, we demonstrate that
the use of dual-specific CAR T cells, in combination
with OVA-Clec9A-TNE, mediates durable remission
of solid tumours in mice.
Clec9A is a C-type lectin receptor that is
selectively expressed by cross-presenting DCs, in
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both humans and mice. We hypothesised that the
OVA antigen delivered by OVA-Clec9A-TNE could
be presented by cross-presenting DCs to both
CAROTI and CAROTII cells to induce antitumour
CAR response in solid tumour models. Excitingly,
the adoptive transfer of CAROT cells in
combination with OVA-Clec9A-TNE treatment
drove significant tumour regression and
generated immune memory responses against
tumour cells in vivo with no observed toxicities,
indicating that this combination overcomes the
limitation of effective antigen presentation for
the generation of antitumour immunity.
Significant CAROTI and CAROTII cell proliferative
responses and CAROTI IFN-c secretion in response
to OVA-Clec9A-TNE treatment were observed. This
response was mediated by the OVA-specific TCR
stimulation. It will be interesting in future studies
to characterise the activation and memory
phenotype of both adoptively transferred CAROT
and host T cells. Phenotypic analysis for memory
cell markers will be helpful to evaluate the
mechanisms by which CAROTI cells accumulate in
tumour sites, and to determine how immune
memory is generated in CAROT cells and/or the
endogenous immune system.
The OVA-Clec9A-TNE drove CAROTI cell
proliferation both in vitro and in vivo, and the
OVA-Clec9A-TNE vaccine boosted CAROT cell
antitumour immunity via OVA-specific TCR
stimulation. Interestingly, although we observed
the expansion of CAROTII cells in vitro, we did not
observe a significant increase in CAROTII cell
numbers in the spleens or tumours in response to
OVA-Clec9A-TNE treatment in tumour-bearing
mice. Targeting antigen to DCs using anti-Clec9A
was shown to elicit both CD8+ and CD4+ T-cell
proliferative responses in na€ıve mice and Clec9A-
OVA-TNE expanded adoptively transferred OTII T
cells in na€ıve mice.7,20 It is possible that CAROTII
cells downregulated CD4 expression upon
persistent vaccine and tumour-derived antigen
stimulation so that the CAROTII cells were not
detected by flow cytometry. Alternatively, the
expanded CAROTII cells might have migrated to
other sites where Clec9A-TNE delivered the
antigen, such as the liver.7 Nevertheless, our
results demonstrated that the OVA-Clec9A-TNE
effectively drives antigen cross-presentation to the
CD8+ CAROTI cells.
Although our previous study demonstrated that
OVA-Clec9A-TNE was superior to soluble OVA
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protein in stimulating OTI and OTII cells in vivo,7
we did not directly compare OVA-Clec9A-TNE to
OVA protein in stimulating CAROT cells and the
antitumour effect. Usually, a strong adjuvant is
required to elicit an effective antitumour T-cell
response, but it will be beneficial in future studies
to include additional experimental control groups
to further strengthen the conclusion.
We observed a high level of cross-presenting
DCs in the spleens of mice that received
combination treatment (Figure 6e). It is likely
these cross-presenting DCs present antigen to
CAROTI cells and facilitate CAROTI cell expansion.
A significant level of tumour-infiltrating DCs
(TIDCs) was also observed in tumours of
combination-treated mice (Figure 6f). A variety of
TIDC subsets exist, where many play a role in
cancer immune-surveillance by driving adaptive
immune responses against tumour antigens.21 In
fact, high frequencies of TIDCs correlate with
favourable prognoses in a variety of cancers.22,23
Elevated levels of TIDCs have been shown to
improve CD8+ T-cell persistence in tumours,24,25
and once expanded, TIDCs can be targeted by
Clec9A-TNE. Thus, elevated TIDC and CAROTI cell
persistence and repeated OVA-Clec9A-TNE dosing
are likely to work together to promote T-cell
memory.
A combination of OVA-Clec9A-TNE and CAROT
cell treatment did not drive significant tumour
regression in the NSG mice bearing E0771-Her2
tumours. As NSG mice do not produce functional
lymphocytes and have compromised DC
function,17,18 our data suggest that endogenous
DC and/or lymphocytic activity is necessary for
combination treatment to mediate tumour
regression. In adoptive transfer experiments in
Her2 transgenic hosts, mice were preconditioned,
receiving total body irradiation at a dose that
depletes endogenous lymphocytes and some DCs.
Clearly, DCs return over the days following
irradiation, but it would be of interest to
determine whether treatment efficacy can be
improved by using preconditioning regimens that
preserve DC populations.
It has been demonstrated that TCR signalling
could abrogate the anti-cancer effect of CD8+ CAR
T cells but not CD4+ T cells through reduced
expansion, increased apoptosis and exhaustion in
a CD19+ ALL murine model. Differential gene
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expression profile revealed that stimulation
through TCR and CAR simultaneously generated
distinct patterns in CD8+ and CD4+ CAR T cells,
with TCR signal more prevalent in CD8+ CAR T
cells and CAR signal more dominant in CD4+ CAR
T cells.26 It is interesting that we observed
significant expansion and infiltration of CD8+
CAROTI cells post-treatment with Clec9A-OVA-
TNE, but did not modulate CD4+ CAROTII cells
(Figure 6). Our data suggest that in our system,
the engagement of TCR mainly enhanced the
activation of CD8+ CAR T cells. The difference is
likely due to the cells that provide the TCR
signalling. In our study, antigen presentation was
provided by the Clec9A+ DCs, while in the
previous study, by the non-cancer cells positive for
a HY male-specific antigen.
Enhancing CAR T-cell antitumour effect by
engaging CAR T-cell TCR has been demonstrated
before, by us6 and others. In our previous study,
we used a vaccinia viral vaccine coding TCR
peptide to stimulate the TCRs on the CAR T cells,
which resulted in the eradication of large tumours
and metastases in a number of murine Her2
tumour models. The TCR peptide is likely
presented by APCs. Subsequently, a number of
studies elegantly demonstrated that by enhancing
CAR T-cell interaction to APCs, large tumours in
difficult murine models could be effectively
treated.27–29 The cells providing TCR signals are
APCs in these studies, which also provide T-cell co-
stimulation and cytokines simultaneously. In
contrast, CAR interacts with tumour cells, which
usually also provide inhibition signals to the CAR
T cells. Therefore, linking CAR T cells with APCs,
either through the stimulation of TCR or other
approaches, could be a valid strategy in
enhancing CAR-mediated tumour cell killing. How
the TCR stimulation enhances CAR-mediated
activity at a cellular level warrants further
investigation.
The clinical application of this approach may
involve transduction of patient T cells with two
gene constructs – one encoding a conventional
CAR and the second, a TCR detecting a known,
tumour peptide presented in MHCI. Transducing
the same T cell with a CAR and a TCR has been
demonstrated feasible.30 Currently, conventional
CAR T-cell therapy has had little success when
applied to solid cancers, but we propose that
incorporating both CAR T cells and simultaneous
vaccination against a tumour antigen detected by
the transgenic TCR presents a promising and
testable avenue for improving patient outcomes
in a variety of poor outcome human cancers.
METHODS
Mice and cell lines
All mouse experiments were approved by the Peter
MacCallum Cancer Centre Animal Experimentation Ethics
Committee (Protocol E582). All the mice were bred at the
Peter MacCallum Cancer Centre (Victoria, Australia), and
mice used for experiments were between 6 and 16 weeks
of age.
The parental murine breast cancer E0771-LMC and
chemically induced colon adenocarcinoma MC38 cell lines
were previously transduced to stably express the full-length
human Her2 antigen under control of the mouse stem cell
virus LTR promoter (MSCV) by retroviral transduction as
described.31 Parental and Her2-expressing cell lines were
cultured in supplemented DMEM media as described
previously.6,29
Tumour inoculation and treatment
C57BL/6-Her2 transgenic or NSG mice were injected
subcutaneously with 5 9 105 E0771-Her2 cells or MC38-Her2
cells. Tumours were allowed to establish over 7–8 days with
sizes ranging between 35 and 45 mm2. Mice were left
untreated or irradiated (4 Gy) before treatment (day 0).
Treated mice received intravenous injections of OVA-
Clec9A-TNE (10 lg 100 lL1), CAROTI (1 9 107 cells
100 lL1) and CAROTII splenocytes (1 9 107 cells 100 lL1)
or a combination of both OVA-Clec9A-TNE, CAROTI and
CAROTII splenocytes (Figure 4a). Treated mice received
intraperitoneal injections of rhIL-2 (1 9 105 IU 200 lL1)
once on day 0, twice on day 1 and once on day 2. Mice that
received the OVA-Clec9A-TNE also received an additional
injection of TNE on day 7. Tumours were measured three
times a week. Mice were culled when tumours grew up to
the ethical limit of 150 mm2 or when showed signs of
distress, including hunched/ruffled appearance or lethargy.
In the rechallenge experiment, surviving, tumour-free
mice were inoculated subcutaneously with 1 9 105 E0771-
Her2 cells 60 days after the primary tumour rejection. Na€ıve
C57BL/6-Her2 transgenic mice were injected at the same
time as the experimental controls.
Preparation of tailored TNEs
Tailored TNE was prepared as previously described.7 Briefly,
OVA protein (Sigma-Aldrich, St Louis, MO, USA) was first
emulsified with a lipophilic surfactant to form a water-in-oil
(W/O) emulsion. Following removal of the water phase, a
solid lipophilic antigen complex was formed and dissolved
in oil to form a solid-in-oil emulsion (S/O). The S/O was
emulsified with a peptide surfactant and the Clec9A
targeting Trp-His (WH) peptide to form the TNE. OVA
carrying TNE (OVA-Clec9A-TNE) were prepared in 5 lg OVA
100 lL1 and 10 lg OVA 100 lL1 doses. An empty-vehicle
TNE was additionally prepared as vehicle control.
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T-cell culture and cellular assays
Spleens were removed from euthanised mice, digested in
1 mg mL1 collagenase III (Worthington, Lakewood, NJ,
USA) and 365 U mL1 of deoxyribonuclease I (DNAse I)
(Thermo Fisher Scientific, Waltham, MA, USA) for 30 min at
37°C. The cells were subsequently incubated with 100 mM
EDTA for additional 10 min at room temperature before
being filtered through 70 lm filters to form a single cell
suspension. After red blood cell lysis, the lymphocytes were
resuspended in supplemented RPMI medium.
Splenocytes were resuspended to 1 9 106 cells mL1 in
supplemented RPMI media with 100 IU mL1 recombinant
human (rh) IL-2 (rhIL-2) (Jiangsu Kingsley Pharmaceutical Co
Ltd, Wuxi, China) and 5 lM SIINFEKL peptide (CAROTI)
(Auspep, Tullamarine, VIC, Australia), 5 lM OVA323-339
peptide (CAROTII) (Auspep) or 0.5 lg mL1 of aCD3 and
0.5 lg mL1 aCD28 (WT). Cells were maintained in a
humidified incubator at 37°C and 5% CO2. Every 48 h, cells
were resuspended to 1 9 106 cells mL1 in fresh
supplemented RPMI media containing 100 IU mL1 of rhIL-
2. Cells were harvested to use for cellular assays or adoptive
transfer 7 days after initial culture.
To test the cytotoxicity of T cells, 5 9 106 E0771-LMC or
E0771-Her2 tumour cells were labelled with 75 lCi
51Chromium (Perkin Elmer, Waltham, MA, USA) and plated at
2 9 104 cells per well in 96-well U-bottom plates. Stimulated
CAROT cells were added to tumour cells at ratios of 40:1, 20:1,
10:1, 5:1 and 1:1. Appropriate cells were used as experimental
controls. After 14-h incubation, supernatant radioactivity was
measured using the Wallac Wizard 1470 automatic gamma
counter (Global Medical Instrumentation Inc., Ramsey, MN,
USA). Percentage-specific lysis was determined using the
following formula: [(Experimental lysis  spontaneous lysis)/
(Total lysis  spontaneous lysis)] 9 100.
Antibodies
Anti-mouse CD3 (clone: 145-2C11) and anti-mouse CD28
(clone: 37.51) antibodies used for splenocyte stimulation
were purchased from BD Biosciences (Franklin Lakes, NJ,
USA). IgG2a isotype (clone: 2A3) was purchased from
BioXCell (Hanover, NH, USA). Antibodies for flow cytometry
and IHC are aCD4-APC-eF780 (clone: RM-45), aCD8a-BV811
(clone: 53-6.7), aCD8 purified (clone: 4SM15), aCD11c-BV785
(clone: N418), aCD11b-APC-eF780 (clone: M170), aCD45.1-
FITC (clone: A20), aClec9A-PE (clone: 10B4), a-c-Myc-AF647
(clone: 9E10), aF4/80-eF450 (clone: BM8), aI-A/I-E-APC
(clone: M5/114.15.2) and aTCR Va2-PE-Cy7 (clone: B20.1).
Flow cytometry, cytokine assay and IHC
Cells for flow cytometric analysis were pelleted and stained
in 50 lL per well of fluorochrome-conjugated antibody
cocktails diluted in FACS buffer (PBS containing 0.5% FCS
and 2 mM EDTA) for 30 min at 4°C in the dark. Following
washing and resuspension in FACS buffer, cells were
labelled with 2 lM Fluorogold viability marker (Biotium,
Hayward, CA, USA) and, 20 lL of Flow-Count Fluorospheres
(Beckman Coulter, Indianapolis, IN, USA) was added to each
sample. Samples were acquired on the BD LSR II (BD
Bioscience). Data were analysed and plotted using FlowJo
v10.4 (Tree Star Inc., Ashland, OR, USA).
For serum cytokine analysis, blood from mice was
collected and allowed to clot for 30 min and centrifuged for
10 min at 1000 g. Serum was collected and stained using the
LEGENDplex mouse inflammation panel kit (BioLegend, San
Diego, CA, USA) according to the manufacturer’s
instructions. To determine cytokine secretion from T cells
in vitro, CAROT cells were stimulated with peptides, and the
supernatant was harvested. IL-2, IFN-c and TNF-a were
analysed using a BD CBA kit according to the manufacturer’s
instructions (BD Bioscience). Samples were analysed using
the BD FACSVerse (BD Bioscience), and data were analysed
using FCAP array software (BD Bioscience).
CD8 IHC was carried out as described previously.29 In
brief, 4 lm tissue sections were stained with 5 lg mL1
antibody against CD8 (clone 4SM15, eBioscience, San Diego,
CA, USA). Antigen retrieval using a high temperature
10 mM citrate buffer (pH = 6) was performed before the
primary antibody incubation. ImmPress horseradish
peroxidase (HRP)-conjugated anti-rat IgG (Vector
Laboratories Ltd, Burlingame, CA, USA) and 3,30-
diaminobenzidine (DAB) substrate (Vector Laboratories Ltd)
were used for colour development. Slides were imaged
using an Olympus VS120 microscope (Olympus, Tokyo,
Japan) and VS-ASW software (Olympus). Images were
analysed using HALO (Indica Labs, Corrales, USA) where
positive staining was quantified as the number of stain
positive divided by tissue area in mm2.
Graphical presentation and statistical
analysis
Data were analysed and graphed using GraphPad Prism 7
(GraphPad, La Jolla, CA, USA) and Microsoft Excel
(Microsoft Corporation, Albuquerque, NM, USA). One-way
ANOVA was used to compare groups of data in in vitro
studies, and Tukey’s range test was used to correct for
multiple comparisons. Tumour growth was compared using
two-way ANOVA, and Tukey’s range test was used to
correct for multiple comparisons. Mouse survival was
compared using the Mantel–Cox test. Significant differences
between comparisons were indicated by P values ≤ 0.05.
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